GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (STU:3G0) » Definitions » Valuation Rank

Altimmune (STU:3G0) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Altimmune Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Altimmune Valuation Rank Related Terms

Thank you for viewing the detailed overview of Altimmune's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (STU:3G0) » Definitions » Valuation Rank
Comparable Companies
EYPT ALDX TSHA ZVRA RGNX TRML STOK ERAS SANA ORIC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ALT:USA 0A4C:UK 3G0:Germany
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Website
https://www.altimmune.com
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.